ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab

Pivotal Trial Results And Pooled Safety Analysis Being Presented

ImmunoGen may need to mount an aggressive education campaign to get in front of issues like blurred vision and keratopathy, with ocular toxicity being common among antibody-drug conjugates.

ImmunoGen is presenting data at ASCO on mirvetuximab soravtansine in platinum-resistant FRa-high ovarian cancer • Source: Shutterstock

ImmunoGen, Inc.’s mirvetuximab soravtansine is likely headed for US Food and Drug Administration accelerated approval for a biomarker-driven form of ovarian cancer by the end of the year, on the back of positive data that the company plans to present at the American Society of Clinical Oncology annual meeting. From there, it may face a competitive threat down the line from a drug with the same target from Bristol Myers Squibb Company, along with potential challenges over ocular toxicity.

ImmunoGen is presenting two sets of data for mirvetuximab at the ASCO annual meeting, being held 3-7 June in Chicago,...